ArticleBJR open2022
What morphological MRI features enable differentiation of low-grade from high-grade soft tissue sarcoma?
Article in BJR open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- MRI characteristics of appendicular soft tissue lymphoma: a retrospective analysis.World journal of surgical oncology · 2026Article
- Automated detection of primary soft tissue sarcomas of the extremities using artificial intelligence and ChatGPT.Frontiers in oncology · 2026Article
- Targeting tumoral heterogeneity in lung cancer: a novel, CT-texture-guided targeted biopsy approach with exome sequencing.NPJ precision oncology · 2025Article
- Review
- Diagnostic utility of MRI-based convolutional neural networks in soft tissue sarcomas: a mini-review.Frontiers in oncology · 2025Review
- Differentiating low- and high-proliferative soft tissue sarcomas using conventional imaging features and radiomics on MRI.BMC cancer · 2024Article
- Predicting the Malignancy Grade of Soft Tissue Sarcomas on MRI Using Conventional Image Reading and Radiomics.Diagnostics (Basel, Switzerland) · 2024Article
- Review
- Local relapse patterns after preoperative radiotherapy of limb and trunk wall soft tissue sarcomas: Prognostic role of imaging and pathologic response factors.Clinical and translational radiation oncology · 2024Article
- New trends in the surgical management of soft tissue sarcoma: The role of preoperative biopsy.World journal of clinical oncology · 2023Review
- Article
- Predicting Interval Pulmonary Metastasis in Extremity Soft Tissue Sarcoma Treated with Preoperative Radiotherapy: A Risk-Stratified Cohort Study of 378 Patients.JB & JS open accessArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the diagnostic performance of morphological MRI features separately and in combination for distinguishing low- from high-grade soft tissue sarcoma (STS). Methods and materials: We retrospectively analysed pre-treatment MRI examinations with T1, T2 with and without fat suppression (FS) and contrast-enhanced T1 obtained in 64 patients with STS categorized histologically as low ( Results: Among all evaluated MRI features, only six features had adequate interobserver reproducibility (kappa>0.5). Multivariate logistic regression analysis revealed a significant association with tumour grade for lesion heterogeneity on FS images, intratumoural enhancement≥51% of tumour volume and peritumoural enhancement for both readers ( Conclusion: A diagnostic MRI score based on tumour heterogeneity, intratumoural and peritumoural enhancement enables identification of lesions that are likely to be high-grade as opposed to low-grade STS. Advances in knowledge: Tumour heterogeneity in Fat Suppression sequence, intratumoural and peritumoural enhancement is identified as signs of high-grade sarcoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.